ClinicalTrials.gg
CompletedNCT05687279Updated Jan 26, 2026Results posted

Study on a Live-attenuated Respiratory Syncytial Virus Vaccine for Assessment of Safety, Transmissibility, and Genetic Stability of the Vaccine Virus Among Close Contacts in Infants and Toddlers 6 to < 24 Months of Age in Puerto Rico (USA)

A Phase 1/2 interventional study of RSVt Vaccine and Control Group in Respiratory Syncytial Virus Infection, sponsored by Sanofi Pasteur, a Sanofi Company. Completed at 6 sites in 2 countries. Open to participants aged 6 Months to 23 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-26.

Sponsored by Sanofi Pasteur, a Sanofi Company (part of Sanofi) · Phase 1/2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
6 Months to 23 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Respiratory Syncytial Virus Infections by Sanofi — none open to participants now, 2 under way, none of them phase 3. Respiratory Syncytial Virus Infections · Sanofi.

Enrollment
10th of 14
80 · median 310
Started
2023
with 2 others
Phase 1/2
5 of 15
none open now
Registered
6th of 15
by date

Among the 15 studies in Respiratory Syncytial Virus Infections by Sanofi, this one is the 10th largest by enrollment of the 14 interventional ones that give a count, is one of 3 that started in 2023, is one of 5 in phase 1/2, and was the 6th registered.

Respiratory Syncytial Virus Infections

306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.

Browse Respiratory Syncytial Virus Infections studies →

Open to participants now

None of the 15 studies in Respiratory Syncytial Virus Infections by Sanofi is open now. The open studies under Respiratory Syncytial Virus Infections, anywhere →

Who these studies take

Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.

This study: 6 Months to 23 Months · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies in Respiratory Syncytial Virus Infections by Sanofi as a file.
02

Study summary

The primary purpose of the study is to assess the shedding, transmission, and genetic stability of the live-attenuated RSVt vaccine after each intranasal vaccination (56 days apart) in infants and toddlers 6 to \< 24 months of age.

Read the detailed description

The duration of each participant's participation is up to 8 months, including the 6 months safety follow-up phone call after the second study intervention administration for the pediatric participants The treatment administration for the pediatric participants will be on D01 and D57 (1 intranasal administration each).

03

Conditions studied

  • Respiratory Syncytial Virus Infection
04

Who can participate

Ages eligible
6 Months to 23 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 6 months to \< 24 months on the day of inclusion (from the day of the 6 months after birth to the day before the 2nd birthday)
  • Participants who are healthy as determined by medical evaluation including medical history.
  • Born at full term of pregnancy (≥ 37 weeks) or born after a gestation period of 27 through 36 weeks and medically stable as assessed by the investigator, based on the following definition: "Medically stable" refers to the condition of premature infants who do not require significant medical support or ongoing management for debilitating disease and who have demonstrated a clinical course of sustained recovery by the time they receive the first dose of study intervention
  • Attends a daycare facility at least 3 days per week and 4 hours per day at which the participant would be in a contact group/playroom of at least one other child 6 to \< 24 months of age who will participate in this study or is a member of a household, which includes at least one other child 6 to \< 24 months of age who will participate in this study

Exclusion criteria

Exclusion Criteria:

  • Known or suspected congenital or acquired immunodeficiency; or receipt of therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)
  • Known systemic to any of the study intervention components, or history of a life-threatening reaction to the study intervention used in the study or to a product containing any of the same substances
  • Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion
  • Any acute febrile illness in the past 48 hours that according to investigator judgment is significant enough to interfere with successful inoculation on the day of vaccination. A prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided.
  • Probable or confirmed ongoing case of COVID-19 at the time of enrollment
  • Member of a household that contains an immunocompromised individual, including, but not limited to:

    • a person who is infected
    • a person who has received chemotherapy within the 12 months prior to study enrollment
    • a person who has received (within the past 6 months) or is receiving (at the time of enrollment) immunosuppressant agents
    • a person living with a solid organ or bone marrow transplant
  • Member of a household that includes, or will include, an infant who is less than 6 months of age at the time of enrollment
  • Attends a daycare facility and shares a daycare room with infants less than 6 months of age, and parent/legally acceptable representative is unable or unwilling to suspend attendance at the daycare facility for 28 days following study intervention administration
  • Any need of supplemental oxygen therapy in a home or hospital setting at the time of enrollment.
  • Participant's mother previous receipt or planned administration of an RSV vaccine or any monoclonal antibody (such as Infliximab) during pregnancy and/or breastfeeding.
  • Receipt or planned receipt of any of the following vaccines prior to or after the first study intervention administration:

    • any influenza vaccine within 7 days prior to and after, or any COVID-19 or inactivated vaccine or live-attenuated rotavirus vaccine within 14 days prior to and after, or
    • any , other than rotavirus vaccine, within 28 days prior to and after
  • Previous receipt of an investigational RSV vaccine or receiving any anti-RSV product (such as ribavirin or RSV Immunoglobulin (IG) or RSV monoclonal antibody) at the time of enrollment.
  • Receipt of immune globulins, blood or blood-derived products in the past 3 months
  • Receipt of intranasal and intra-ocular medications within 3 days prior to study enrollment
  • Receipt at the time of enrollment or previous receipt of salicylate (aspirin) or salicylate-containing products
  • Participation at the time of study enrollment (or in the 6 weeks preceding the first study intervention administration) or planned participation during the present study period in another clinical study investigating a vaccine, drug, medical device, or medical procedure
  • Deprived of freedom in an emergency setting, or hospitalized involuntarily
  • Identified as a natural or adopted child of the Investigator or employee with direct involvement in the proposed study

The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    RSVt Vaccine Group

    2 intranasal administrations (56 days apart) of the RSVt vaccine at D01 and D57

    Biological: RSVt Vaccine

  • Placebo comparator
    Control Group

    2 intranasal administrations (56 days apart) of the placebo at D01 and D57

    Other: Control Group

Interventions

  • BiologicalRSVt Vaccine

    Pharmaceutical Form: Suspension of virus in a nasal spray Route of Administration: Intranasal

  • OtherControl Group

    Pharmaceutical Form: Suspension of virus in a nasal spray Route of Administration: Intranasal

06

What researchers measure

Primary outcomes

  1. Percentage of Placebo Receiving Pediatric Participants With Vaccine Virus Detected in Nasal Swabs After the First Vaccination

    Nasal swabs were collected to assess the presence of vaccine virus after first vaccination. Vaccine virus transmission was defined as presence of detected vaccine virus confirmed by RSVt quantitative reverse transcription polymerase chain reaction (qRT-PCR) assay (vaccine virus shedding \>=lower limit of detection \[LOD=2.80 log10 copies/mL\]) in pediatric participants receiving placebo. Percentages are rounded off to the tenth decimal place.

    Time frame: Pre-vaccination on Day 1 and post-vaccination on Days 4, 8, 11, 15, 18 and 22

  2. Titer of Vaccine Virus Shedding in All Pediatric Participants Detected in Nasal Swabs

    Nasal swabs were collected to assess the shedding of the attenuated RSV vaccine strain and quantified by RSVt qRT PCR assay. Quantified virus shedding was defined as vaccine virus shedding \>=lower limit of quantification (LLOQ=3.37 log10 copies/mL).

    Time frame: Pre-vaccination on Day 1 and post-vaccination on Days 4, 8, 11, 15, 18, 22, 64 and 71

  3. Percentage of Placebo Receiving Pediatric Participants With Detected Shedding Who Showed Any Genetic Sequence Variation After Each Vaccination

    Nasal swabs were collected to identify the difference in genetic sequence of mutated vaccine virus segments compared to the reference strain vaccine virus isolates in the vaccine virus positive swabs from pediatric participants receiving placebo after each vaccination. Detected virus shedding was defined as vaccine virus shedding \>=LOD (2.80 log10 copies/mL).

    Time frame: Up to 21 days after each vaccination (Day 1 to Day 22 and Day 57 to Day 78)

Secondary outcomes

  1. Geometric Mean Titers (GMTs) of RSV A Serum Neutralizing Antibody (nAb) Titers

    Serum samples were collected at specified timepoints for immunogenicity assessments. RSV A serum neutralizing antibody titers were evaluated by microneutralization (MN) assay.

    Time frame: Pre-vaccination on Day 1 (first vaccination) and Day 57 (second vaccination) and up to 28 days after second vaccination, Day 85

  2. Secondary: Geometric Mean Titers of RSV Serum Anti-F Immunoglobulin G (IgG) Enzyme-linked Immuno-adsorbant Assay (ELISA) Antibody

    Serum samples were collected at specified timepoints for immunogenicity assessments. Antibodies to RSV F antigen were measured using the anti RSV F IgG ELISA method.

    Time frame: Pre-vaccination on Day 1 (first vaccination) and Day 57 (second vaccination) and up to 28 days after second vaccination, Day 85

  3. Number of Participants With Immediate Unsolicited Adverse Events (AEs)

    An AE was any untoward medical occurrence in a clinical study participant temporally associated with the use of study vaccine, whether or not considered related to the study vaccine. An unsolicited AE was an observed AE that did not fulfill the conditions of solicited reactions, i.e., pre-listed in the case report form (CRF) in terms of diagnosis and onset window post-vaccination. All participants were observed for 30 minutes after each vaccination and any unsolicited AEs that occurred during that time were recorded as immediate unsolicited AEs.

    Time frame: Up to 30 minutes after each vaccination (Days 1 and 57)

  4. Number of Participants With Solicited Administration Site Reactions and Systemic Reactions

    A solicited reaction was an expected adverse reaction (AR) (sign or symptom) observed and reported under the conditions (nature and onset) pre-listed in the protocol and CRF and considered as related to the study vaccine administered. An administration site reaction was an AR at and around the administration/injection site and were commonly inflammatory reactions. Solicited systemic reactions were systemic AEs and those occurring during the specified collection period were always considered related to the vaccine even if there was evidence of alternative etiology.

    Time frame: Up to 21 days after each vaccination (Day 1 to Day 22 and Day 57 to Day 78)

  5. Number of Participants With Unsolicited Adverse Events

    An AE was any untoward medical occurrence in a clinical study participant temporally associated with the use of study vaccine, whether or not considered related to the study vaccine. An unsolicited AE was an observed AE that did not fulfill the conditions of solicited reactions, that is, pre-listed in the CRF in terms of diagnosis and onset window post-vaccination.

    Time frame: Up to 28 days after each vaccination (Day 1 to Day 29 and Day 57 to Day 85)

07

Results

Posted Jan 26, 2026

Participant flow

The study was conducted at 3 sites in Puerto Rico from 06-Feb-2023 to 27-Dec-2024.

Participant flow — Overall Study
MilestoneRSVtPlacebo
Started4040
Completed3538
Not completed52

Outcome measures

PrimaryPercentage of Placebo Receiving Pediatric Participants With Vaccine Virus Detected in Nasal Swabs After the First Vaccination

Nasal swabs were collected to assess the presence of vaccine virus after first vaccination. Vaccine virus transmission was defined as presence of detected vaccine virus confirmed by RSVt quantitative reverse transcription polymerase chain reaction (qRT-PCR) assay (vaccine virus shedding \>=lower limit of detection \[LOD=2.80 log10 copies/mL\]) in pediatric participants receiving placebo. Percentages are rounded off to the tenth decimal place.

Time frame:
Pre-vaccination on Day 1 and post-vaccination on Days 4, 8, 11, 15, 18 and 22
Reported as:
Number · percentage of participants
Percentage of Placebo Receiving Pediatric Participants With Vaccine Virus Detected in Nasal Swabs After the First Vaccination
percentage of participantsPlacebo
Day 10 (0 to 10.9)
Day 40 (0 to 9.7)
Day 80 (0 to 9.7)
Day 110 (0 to 9.7)
Day 150 (0 to 10.0)
Day 180 (0 to 9.7)
Day 220 (0 to 10.3)
PrimaryTiter of Vaccine Virus Shedding in All Pediatric Participants Detected in Nasal Swabs

Nasal swabs were collected to assess the shedding of the attenuated RSV vaccine strain and quantified by RSVt qRT PCR assay. Quantified virus shedding was defined as vaccine virus shedding \>=lower limit of quantification (LLOQ=3.37 log10 copies/mL).

Time frame:
Pre-vaccination on Day 1 and post-vaccination on Days 4, 8, 11, 15, 18, 22, 64 and 71
Reported as:
Mean · log10 copies/mL
Titer of Vaccine Virus Shedding in All Pediatric Participants Detected in Nasal Swabs
log10 copies/mLRSVtPlacebo
Day 84.33 ± 0.649—
Day 114.33 ± 0.617—
Day 224.72—
Day 643.55 ± 0.014—
PrimaryPercentage of Placebo Receiving Pediatric Participants With Detected Shedding Who Showed Any Genetic Sequence Variation After Each Vaccination

Nasal swabs were collected to identify the difference in genetic sequence of mutated vaccine virus segments compared to the reference strain vaccine virus isolates in the vaccine virus positive swabs from pediatric participants receiving placebo after each vaccination. Detected virus shedding was defined as vaccine virus shedding \>=LOD (2.80 log10 copies/mL).

Time frame:
Up to 21 days after each vaccination (Day 1 to Day 22 and Day 57 to Day 78)

No measurements were reported for this outcome.

SecondaryGeometric Mean Titers (GMTs) of RSV A Serum Neutralizing Antibody (nAb) Titers

Serum samples were collected at specified timepoints for immunogenicity assessments. RSV A serum neutralizing antibody titers were evaluated by microneutralization (MN) assay.

Time frame:
Pre-vaccination on Day 1 (first vaccination) and Day 57 (second vaccination) and up to 28 days after second vaccination, Day 85
Reported as:
Geometric mean · 1/dilution
Geometric Mean Titers (GMTs) of RSV A Serum Neutralizing Antibody (nAb) Titers
1/dilutionRSVtPlacebo
Day 153.4 (29.7 to 95.9)47.9 (25.2 to 90.8)
Day 57167 (95.5 to 294)65.3 (30.8 to 138)
Day 85219 (126 to 382)60.0 (26.6 to 135)
SecondarySecondary: Geometric Mean Titers of RSV Serum Anti-F Immunoglobulin G (IgG) Enzyme-linked Immuno-adsorbant Assay (ELISA) Antibody

Serum samples were collected at specified timepoints for immunogenicity assessments. Antibodies to RSV F antigen were measured using the anti RSV F IgG ELISA method.

Time frame:
Pre-vaccination on Day 1 (first vaccination) and Day 57 (second vaccination) and up to 28 days after second vaccination, Day 85
Reported as:
Geometric mean · Elisa Units/mL
Secondary: Geometric Mean Titers of RSV Serum Anti-F Immunoglobulin G (IgG) Enzyme-linked Immuno-adsorbant Assay (ELISA) Antibody
Elisa Units/mLRSVtPlacebo
Day 192.2 (45.5 to 187)85.6 (39.3 to 186)
Day 57249 (130 to 475)115 (49.7 to 265)
Day 85383 (205 to 714)129 (52.6 to 317)
SecondaryNumber of Participants With Immediate Unsolicited Adverse Events (AEs)

An AE was any untoward medical occurrence in a clinical study participant temporally associated with the use of study vaccine, whether or not considered related to the study vaccine. An unsolicited AE was an observed AE that did not fulfill the conditions of solicited reactions, i.e., pre-listed in the case report form (CRF) in terms of diagnosis and onset window post-vaccination. All participants were observed for 30 minutes after each vaccination and any unsolicited AEs that occurred during that time were recorded as immediate unsolicited AEs.

Time frame:
Up to 30 minutes after each vaccination (Days 1 and 57)
Reported as:
Count of participants · Participants
Number of Participants With Immediate Unsolicited Adverse Events (AEs)
ParticipantsRSVtPlacebo
Number of Participants With Immediate Unsolicited Adverse Events (AEs)00
SecondaryNumber of Participants With Solicited Administration Site Reactions and Systemic Reactions

A solicited reaction was an expected adverse reaction (AR) (sign or symptom) observed and reported under the conditions (nature and onset) pre-listed in the protocol and CRF and considered as related to the study vaccine administered. An administration site reaction was an AR at and around the administration/injection site and were commonly inflammatory reactions. Solicited systemic reactions were systemic AEs and those occurring during the specified collection period were always considered related to the vaccine even if there was evidence of alternative etiology.

Time frame:
Up to 21 days after each vaccination (Day 1 to Day 22 and Day 57 to Day 78)
Reported as:
Count of participants · Participants
Number of Participants With Solicited Administration Site Reactions and Systemic Reactions
ParticipantsRSVtPlacebo
Solicited administration site reaction3032
Solicited systemic reaction2625
SecondaryNumber of Participants With Unsolicited Adverse Events

An AE was any untoward medical occurrence in a clinical study participant temporally associated with the use of study vaccine, whether or not considered related to the study vaccine. An unsolicited AE was an observed AE that did not fulfill the conditions of solicited reactions, that is, pre-listed in the CRF in terms of diagnosis and onset window post-vaccination.

Time frame:
Up to 28 days after each vaccination (Day 1 to Day 29 and Day 57 to Day 85)
Reported as:
Count of participants · Participants
Number of Participants With Unsolicited Adverse Events
ParticipantsRSVtPlacebo
Number of Participants With Unsolicited Adverse Events812

Adverse events

Collected over From date of first vaccination (Day 1) up to 6 months after the last study vaccination, approximately 237 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
RSVt0/39 (0%)2/39 (5.1%)11/39 (28.2%)
Placebo0/39 (0%)4/39 (10.3%)14/39 (35.9%)
Most frequent serious events
Most frequent serious events
EventRSVtPlacebo
BronchiolitisInfections and infestations2/392/39
GastroenteritisInfections and infestations0/391/39
InfluenzaInfections and infestations1/390/39
Oral HerpesInfections and infestations0/391/39
Most frequent other events
Most frequent other events
EventRSVtPlacebo
Decreased AppetiteMetabolism and nutrition disorders11/3914/39

Baseline characteristics

Randomized set included those pediatric participants for whom a study vaccine group was allocated.

Age, Categorical
Age, Categorical(Participants)RSVtPlaceboTotal
<=18 years404080
Between 18 and 65 years000
>=65 years000
Age, Continuous
Age, Continuous(months)RSVtPlaceboTotal
Mean15.1 ± 5.5515.8 ± 5.8115.4 ± 5.66
Sex: Female, Male
Sex: Female, Male(Participants)RSVtPlaceboTotal
Female162339
Male241741
Race (NIH/OMB)
Race (NIH/OMB)(Participants)RSVtPlaceboTotal
American Indian or Alaska Native011
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American123
White292756
More than one race101020
Unknown or Not Reported000
08

Study locations

6 sites
  • Meridian Clinical Research Norfolk Site Number : 8400003
    Norfolk, Nebraska 68701, United States
  • Velocity Clinical Research, Omaha Site Number : 8400001
    Omaha, Nebraska 68134, United States
  • Investigational Site Number : 6300004
    Bayamón, 00960, Puerto Rico
  • Investigational Site Number : 6300002
    Carolina, 984, Puerto Rico
  • Investigational Site Number : 6300003
    Guayama, 00784, Puerto Rico
  • Investigational Site Number : 6300001
    San Juan, 00918, Puerto Rico
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2023 to primary completion in Dec 2024, 22 months.

Results were first posted in Jan 2026, 1 year after primary completion.

Of 16 phase 1/2 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 27. This study's 22 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2023
First posted
Jan 18, 2023
StartActual
Feb 6, 2023
Primary completionActual
Dec 27, 2024
CompletionActual
Dec 27, 2024
Results first posted
Jan 26, 2026
Last update
Jan 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05687279
Responsible party
Sponsor
First posted
Jan 18, 2023
Start date
Feb 6, 2023
Primary completion
Dec 27, 2024
Completion
Dec 27, 2024
Results posted
Jan 26, 2026
Last update
Jan 26, 2026

Study contacts

Clinical Sciences & Operations
study director · Sanofi Pasteur, a Sanofi Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion